Navigation Links
Dr. Magnus Persson Joins Cerecor's Board of Directors
Date:8/28/2012

BALTIMORE, Aug. 28, 2012 /PRNewswire/ -- Cerecor Inc. announced today that Magnus Persson, MD Ph.D. has joined the company's Board of Directors. Dr. Persson was one of the original team members at Healthcap, one of the largest biotechnology venture capital firms in Europe.  He became Partner before the first fund was raised in 1996, participated in raising in excess of US$ 1B in international institutional investments and was responsible for deal sourcing, screening and the monitoring of investments as Board representative. He invested in 85 Companies of which 24 have made successful IPO's in various European exchanges and on NASDAQ. Dr. Persson trained at the Karolinska Institute in Stockholm and prior to Healthcap led Phase II and III clinical programs in the Pharmaceutical Industry.

(Logo:  http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

Magnus currently serves on the Board of Directors of AscendxSpine (private), ConcitPharma (private), Sjalbadan (private) and the Swedish Center for Medical Nanotechnology at Karolinska Institute.  He has previously served on the Boards of Chemocentryx (public), Arpida (public), Tripep (public), PTC Therapeutics (private), Alba Therapeutics (private), Trigen (private), Apoxis (private), SpineVision (private), Carmot Therapeutics (private), MIPS Technology (private), LICA Pharmaceuticals (private), IDEA (private), Neoventa (private) and Prolifix (public).

"Magnus has a vast network within international biopharmaceutical financing communities and has a track record of delivering value for shareholders and stakeholders while expanding the potential of those people who report to him," said Blake Paterson, M.D., the CEO of Cerecor.   Dr. Persson added, "I am delighted to join the Board of Directors of Cerecor and to assist its outstanding management in building a novel and truly differentiated neuroscience Company."

In addition to Drs. Persson and Paterson, Cerecor's Board is Chaired by Dr. Sol Barer and further comprised of members Dr. Gene Bauer and Mssrs. Isaac Blech, John Catsimatidis, and Cary Sucoff.

About Cerecor:  Cerecor Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and organized in April 2011 in partnership with various laboratories at Johns Hopkins Medical Institute. Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.

Contact:  John Dierkes, Kennedy Advisors, +1-410-522-8707


'/>"/>
SOURCE Cerecor Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
2. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
3. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
4. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
5. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
6. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
7. Remedy Informatics Joins LongView International Technology Solutions Team to Win CIO-SP3 Contract Award
8. Tara Dall, MD Joins Health Diagnostic Laboratory (HDL, Inc.) as Chief Medical Officer
9. Double Helix Joins McCann Health
10. Prairie Education & Research Cooperative Joins MedNet Solutions iMedNet CRO Partner Program
11. Don Hubbard Joins Checkpoint Surgical As VP Of Sales And Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , United Kingdom and  BOSTON , March ... provider Linguamatics today announced a partnership ... . The agreement allows pharmaceutical companies to extract ... I2E text mining technology. ... 18 of the top 20 global pharmaceutical companies. ...
(Date:3/28/2017)... Calif. , March 28, 2017  AcelRx ... focused on the development and commercialization of innovative ... announced that the European Medicines Agency (EMA) has ... tablet, 30 mcg) Marketing Authorisation Application (MAA) has ... the MAA is underway. The MAA for ARX-04 ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... Revolution for Truth has organized the ... parental rights and civil liberties, and to restore transparency within government agencies responsible ... with a press conference taking place Friday morning calling on President Trump to ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of ... Dr. Wentz talked about journey and research recently on a blog and discussed some ... only solution to deal with thyroid disease. , Dr. Wentz completed her graduation ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... software and services, is proud to announce it has joined the National Association ... representing the interests of chronically ill, disabled, and dying Americans of all ages ...
(Date:3/28/2017)... Pittsburgh, PA (PRWEB) , ... March 28, 2017 ... ... built for and by physicians, announced today the launch of a free, public-facing ... The Via Cost Analyzer (VCA) was developed to provide comparative information to patients, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
Breaking Medicine News(10 mins):